רספרים

Country: Israel

Language: Hebrew

Source: Ministry of Health

Active ingredient:

SULPHAMETHOXAZOLE; TRIMETHOPRIM

Available from:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

ATC code:

J01EE01

Pharmaceutical form:

תרחיף

Composition:

SULPHAMETHOXAZOLE 200 MG / 5 ML; TRIMETHOPRIM 40 MG / 5 ML

Administration route:

פומי

Prescription type:

מרשם נדרש

Manufactured by:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Therapeutic group:

SULFAMETHOXAZOLE AND TRIMETHOPRIM

Therapeutic area:

SULFAMETHOXAZOLE AND TRIMETHOPRIM

Therapeutic indications:

Treatment of urinary tract infections due to susceptible strains of the following organisms: - Escherichia coli - Klebsiella - Enterobacter - Proteus mirabilis - Proteus vulgaris - Proteus morganii. Treatment of acute otitis media in children due to susceptible strains of Haemophilus influenzae or Streptococcus pneumoniae. To date there are limited data available as to the safety of repeated use of Resprim in infants under 2 years of age. Resprim is not indicated for prophylactic or prolonged administration in otitis media at any age. Treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Haemophilus influenzae or Streptococcus pneumoniae. Treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei. Resprim is also indicated in the treatment of documented Pneumocystis carinii pneumonitis.

Authorization date:

2012-01-31